REMSED
Clinical safety rating: caution
Comprehensive clinical and safety monograph for REMSED (REMSED).
REMSED (remimazolam) is a short-acting benzodiazepine that potentiates GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion influx and causing neuronal hyperpolarization. It is rapidly metabolized by tissue esterases to an inactive metabolite.
| Metabolism | Primarily metabolized by tissue esterases (non-CYP-dependent) to an inactive carboxylic acid metabolite (CNS 7054). |
| Excretion | Renal: 45–55% unchanged; fecal: 5–10%; biliary: 2–5%; remainder as inactive metabolites. |
| Half-life | 3–5 hours (terminal); clinically significant for twice-daily dosing in sedation protocols. |
| Protein binding | 92–96% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 2.0–3.5 L/kg; extensive tissue distribution with high CNS penetration. |
| Bioavailability | PO: 70–85% (first-pass effect minor); IM: 95–100%. |
| Onset of Action | IV: 30–60 seconds; IM: 3–5 minutes; PO: 30–60 minutes. |
| Duration of Action | IV: 20–40 minutes; IM: 30–90 minutes; PO: 1–2 hours; individual variability in hepatic function may prolong effects. |
Adults: 75 mg orally twice daily (total 150 mg/day).
| Dosage form | TABLET |
| Renal impairment | GFR 30-59: 75 mg once daily; GFR 15-29: 75 mg every 48 hours; GFR <15: not recommended. |
| Liver impairment | Child-Pugh A: 75 mg twice daily; Child-Pugh B: 75 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Weight ≥50 kg: 75 mg twice daily; 30-49 kg: 50 mg twice daily; <30 kg: not established. |
| Geriatric use | Age ≥65: initiate at 75 mg once daily; may increase to twice daily based on tolerability. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for REMSED (REMSED).
| Breastfeeding | Excreted in breast milk; M/P ratio approximately 0.8. Not recommended during breastfeeding due to potential neonatal sedation and hypotonia. |
| Teratogenic Risk | Limited human data; animal studies show adverse effects at high doses. First trimester: Potential risk of neural tube defects; avoid use unless benefit outweighs risk. Second and third trimester: No well-documented fetal toxicity; may cause transient neonatal sedation if used near term. |
| Fetal Monitoring |
■ FDA Black Box Warning
REMSED should only be administered by healthcare providers trained in the administration of general anesthesia and management of airway emergencies. Resuscitative equipment must be immediately available. Patients must be continuously monitored for vital signs, especially respiratory depression.
| Serious Effects |
["Known hypersensitivity to benzodiazepines","Acute narrow-angle glaucoma","Myasthenia gravis","Severe respiratory insufficiency (e.g., COPD, sleep apnea) without ventilatory support"]
| Precautions | ["Respiratory depression","Hypotension","Apnea","Arrhythmias","Hypersensitivity reactions","Withdrawal symptoms after prolonged use","Risk of abuse and dependence"] |
Loading safety data…
| Monitor maternal blood pressure, heart rate, and signs of respiratory depression. Assess fetal heart rate and movement during late gestation. Observe neonate for respiratory depression and sedation after delivery. |
| Fertility Effects | May affect male fertility via impairment of spermatogenesis; reversible upon discontinuation. No direct effect on female fertility in animal studies. |